Skip to content

Press Releases and Events

PRESS RELEASES AND EVENTS

Events

There are currently no events to display.

Archived Events

There are currently no events to display.

Press Releases

Date Title and Summary View
Toggle Summary Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults
Intra-Cellular Therapies launches LYTAlink™, a comprehensive patient affordability and access program for CAPLYTA NEW YORK , April 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of
View HTML
Toggle Summary Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia
NEW YORK , March 23, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA (lumateperone) is now available to
View HTML
Toggle Summary Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
NEW YORK , March 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year
View HTML
Toggle Summary Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast
NEW YORK , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live
View HTML
Toggle Summary Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the grant to four new employees of inducement stock
View HTML
Toggle Summary Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry
NEW YORK , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced the publication of results from its CAPLYTA (lumateperone)
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the 9th Annual SVB Leerink Global Healthcare Conference
NEW YORK , Feb. 18, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and
View HTML
Toggle Summary Intra-Cellular Therapies Prices Public Offering of Common Stock
NEW YORK , Jan. 07, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $29.50 per share.
View HTML
Toggle Summary Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
NEW YORK , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company, today announced that it has commenced an underwritten public offering of 10,000,000 shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends
View HTML
Toggle Summary Intra-Cellular Therapies to Present at the 38th Annual J.P. Morgan Healthcare Conference
NEW YORK , Jan. 02, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled
View HTML
Toggle Summary FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults
NEW YORK , Dec. 23, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that CAPLYTA ® (lumateperone) has been approved by the U.S.
View HTML
Toggle Summary Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology
Bipolar depression:  Study 404, A Phase 3 Clinical Trial of lumateperone for the treatment of Bipolar Depression, investigating the potential of lumateperone as a new option for the treatment of depressive episodes in patients suffering from Bipolar I or Bipolar II disorder.  Schizophrenia:
View HTML
Toggle Summary Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American College of Neuropsychopharmacology
NEW YORK , Dec. 04, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company will be presenting at the 58th Annual Meeting of the
View HTML
Toggle Summary Intra-Cellular Therapies Provides Corporate Update and Reports Third Quarter 2019 Financial Results
NEW YORK , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today provided a corporate update and announced its financial results for the third quarter
View HTML
Toggle Summary Intra-Cellular Therapies to Host Third Quarter 2019 Financial Results Conference Call and Webcast
NEW YORK , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies , Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m.
View HTML